Educational, Clinical and Quality Projects
The goal of this program is to foster the scholarship and career development of clinical and educational leaders among Department of Medicine faculty. The Department of Medicine hopes to sponsor 3-4 pilot projects annually with funding levels targeted to meet the scope of the proposal (approximately $10,000 to $40,000 per project). The intent is to fund sustaining innovative programs that will lead to scholarly dissemination. Awarded funds may be used to support DOM faculty time and effort, but are best used to defray other associated costs of the proposed project including administrative and statistical support, and attendance for presentation at an appropriate professional meeting. While all applications will be considered, weight will be given to proposals with:
- Junior investigators who are the principal investigator (trainees, senior instructors or assistant professors)
- Strong senior faculty mentorship (both process and content)
- Innovative ideas of anticipated changes in the clinical and educational landscape, not just current needs
- Appropriate scope and feasibility to match the funding level
- A plan for dissemination of findings beyond URMC
To be eligible, the principal investigator (PI) must have a primary appointment in the Department of Medicine.
An initial formatted letter of intent and an adapted clinical and educational biosketch for both the PI and mentor as a single pdf are due by November 30th, 2018. These applications will be scored by a team of senior faculty. On January 9th, 2019 meritorious applications will be invited for a full 6 page submission due March 1st, 2019, with winners announced in April 2019, and a funding start date of July 1st, 2019
Submit applications by November 30, 2018 as a single pdf to Rachel_Oppelt@urmc.rochester.edu
Recipients will be asked to present their findings at the end of the funding year to the Department of Medicine.
Submissions that do not conform to these instructions will not be reviewed
Form and Documentation
Questions can be addressed to Marc Berliant or Brett Robbins.